New Mexico is one of six states that has begun using artificial intelligence to comply with a major Medicaid overhaul contained in the “One Big Beautiful Bill Act” that President Donald Trump signed ...

SpaceX notified investors that it is executing a 5-for-1 stock split, a move that will reduce the price investors will pay for each share offered in its impending initial public offering. Shareholders ...

Julia Sullivan is a health and fitness writer, editor and content strategist well as a certified personal trainer. Her byline is in many publications from Harper's Bazaar to SELF Magazine to brand ...

A common side effect of many GLP-1 drugs is hair loss. It's creating a growing market for hair treatment products. Companies like Redken, Nutrafol and KeraFactor are leaning into the innovation and ...

The use of GLP-1 medications for weight loss continues to rise. One drawback associated with GLP-1 medications is that weight loss not only includes fat loss, but muscle loss as well. A new study ...

Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.

The water restrictions taking effect Monday in Raleigh are expected to last more than a month, according to a city spokesperson. City of Raleigh environmental coordinator Ed Buchan estimated that the ...

Not too long ago I would have said I was one of the least likely people to be tempted by GLP-1s like Wegovy or Zepbound. My weight has always been average. I have no medical conditions, and more than ...

Denver Board of Water Commissioners adopted a resolution approving the implementation of temporary drought pricing at a meeting Wednesday. Denver Water said that the drought pricing will apply ...

Corebridge Financial and Equitable Holdings have agreed to an all-stock merger valued at approximately $22 billion that will create a life insurance, annuity, wealth and asset management company ...

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a ...